EvolveImmune Logo.jpg
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 nov. 2022 09h00 HE | EvolveImmune
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
24 oct. 2022 07h00 HE | EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
18 oct. 2022 07h00 HE | EvolveImmune
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development
07 juil. 2022 07h00 HE | EvolveImmune
BRANFORD, Conn., July 07, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional cancer biotherapeutics, today announced the...